eLung: A Multicenter, Randomized Phase IIb Trial of “Standard” Platinum Doublets plus Cetuximab (CET) as First-line Treatment of Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

L. Schwartzberg